Notably, patients previously categorized as having favorable-risk AML might have been reclassified as having intermediate-risk disease and vice versa, based on the presence or absence of MRD, particularly relevant in cases of NPM1-mutant AML [24,25,26]. Here, NPM1 is linked to acute myeloid leukemia.